Further, there were fewer migrated cells in the RARRES1 + lenvatinib group than in cells treated with lenvatinib alone, indicating that RARRES1 overexpression promoted HCC cell sensitivity to lenvatinib (Fig. 4B). The gene discussed is RARRES1; the disease is hepatocellular carcinoma.